MARKET

ELDN

ELDN

Eledon Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.65
-0.14
-2.06%
Closed 16:00 09/24 EDT
OPEN
6.77
PREV CLOSE
6.79
HIGH
6.85
LOW
6.56
VOLUME
51.31K
TURNOVER
--
52 WEEK HIGH
27.32
52 WEEK LOW
5.91
MARKET CAP
95.14M
P/E (TTM)
-0.7640
1D
5D
1M
3M
1Y
5Y
Eledon Pharmaceuticals to Present at Two Investor Conferences in September
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic ...
GlobeNewswire · 09/01 20:05
A Duo of Net Current Asset Value Stock Picks to Consider
GuruFocus News · 08/23 13:48
Eledon Pharmaceuticals Q2 EPS $(0.50) Beats $(0.57) Estimate
Eledon Pharmaceuticals (NASDAQ:ELDN) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.57) by 12.28 percent. This is a 233.33 percent decrease over losses of $(0.15) per
Benzinga · 08/12 20:38
Eledon Pharmaceuticals EPS beats by $0.07
Eledon Pharmaceuticals (NASDAQ:ELDN): Q2 GAAP EPS of -$0.50 beats by $0.07. The company had approximately $101.1 million in cash and cash equivalents as of June 30, 2021, compared to $114.2
Seekingalpha · 08/12 20:11
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 12:09
Earnings Scheduled For August 12, 2021
  Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
Benzinga · 08/12 08:14
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the...
Benzinga · 08/08 14:03
Eledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021
Eledon Pharmaceuticals ("Eledon") (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amy...
GlobeNewswire · 08/02 12:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ELDN. Analyze the recent business situations of Eledon Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ELDN stock price target is 30.80 with a high estimate of 39.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 48
Institutional Holdings: 10.11M
% Owned: 70.66%
Shares Outstanding: 14.31M
TypeInstitutionsShares
Increased
12
2.22M
New
7
416.91K
Decreased
7
99.60K
Sold Out
6
1.18M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Keith Katkin
President/Chief Scientific Officer/Director
Steven Perrin
Chief Executive Officer/Director
David-Alexandre Gros
Chief Financial Officer
Paul Little
Chief Compliance Officer/General Counsel/Secretary
Bryan Smith
Other
Jeff Bornstein
Other
David Hovland
Independent Director
Jan Hillson
Independent Director
June Lee
Independent Director
Gary Lyons
Independent Director
John McBride
Independent Director
Walter Ogier
No Data
About ELDN
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for persons living with an autoimmune disease, which requires an organ or cell-based transplant or living with amyotrophic lateral sclerosis (ALS). The Company's lead product candidate, AT-1501, is a humanized monoclonal antibody (mAb) designed to target CD40 Ligand (CD40L) also called CD154), a molecule expressed on the surface of human immune system T cells. The central role of CD40 or CD40L signaling in generating pro-inflammatory responses makes it a candidate for therapeutic intervention in autoimmune disease, induction and maintenance of transplant tolerance and neuroinflammation. Blocking the activation of the CD40L pathway prevents acute and long-term allograft transplant rejection in multiple animal species and ameliorates disease progression and pathology in preclinical models of autoimmunity and ALS.

Webull offers kinds of Eledon Pharmaceuticals Inc stock information, including NASDAQ:ELDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELDN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ELDN stock methods without spending real money on the virtual paper trading platform.